



FOR IMMEDIATE RELEASE

SciTech Development receives IRB Approval to enter the clinic at Rush University Medical Center (RUMC)

(GROSSE POINTE FARMS, MI) July 2, 2020 – SciTech Development, LLC, a clinical stage specialty pharmaceutical company focused on novel, advanced drug delivery mechanisms for use with cancer therapeutics, is pleased to announced that it has received IRB Approval to enter the clinic at Rush University Medical Center (RUMC) for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL).

SciTech’s Investigational New Drug Application (IND) for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL) was accepted last December.

Additionally, the FDA has granted Orphan Drug Designation status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Solid preclinical and clinical data makes the case for the use of

fenretinide in the treatment of additional blood disorders and solid tumors such as small cell lung, breast, pancreatic, neuroblastoma and other cancers. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | eth@scitechdevelopment.com

About SciTech Development

SciTech Development, LLC is a clinical stage, specialty pharmaceutical development company currently bringing to market a proven drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the metropolitan Detroit, Michigan area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. Additional information regarding SciTech's nanoparticle technology and ST-001



RUSH UNIVERSITY MEDICAL CENTER
1653 WEST CONGRESS PARKWAY
CHICAGO, ILLINOIS, 60612-3833

OFFICE OF RESEARCH AFFAIRS
312.942.5498
312.942.2874 (FAX)



**I
R
B** 

Full Board Initial Approval Notification

The following research activity has been reviewed and approved by Institutional Review Board Institutional Review Board #2 at Rush University Medical Center. The Institutional Review Board confirms that the research meets approval criteria set forth in Federal Regulations found at 45 CFR 46.111 and 21 CFR 312.61 and any other applicable governing regulations or subparts. Please note the date for continuing review. Although you will be notified near the time for continuing review, it is your responsibility to assure that your project receives ongoing IRB approval.

ORA Number: 16062802-IRB01

Principal Investigator: Timothy Kuzel
Project Title: A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a fenretinide phospholipid suspension (12.5 mg/mL) for Intravenous Infusion

Date of approval: 6/24/2020
Due for continuing/annual review: 6/24/2021



COI Management Plan: Not Applicable
Approved Study Protocol Document: Exhibit A - Protocol-v-12-3-2019.pdf.pdf
Approved Other Document: Patient Handout and Wallet Card 1-23-2020.docx.pdf
Approved Drug Document: Investigators Brochure_ST-001-v1-2.pdf.pdf
Approved Consent Document: 2020.06.03 ST001 Main ICF CLEAN.docx.pdf



SciTech Development, LLC

nanoFenretinide drug product is available from SciTech Development, LLC by calling +1-313-938-5517 or online at <https://www.scitechdevelopment.com/>.

About Rush University Medical Center (RUMC)

Named a top U.S. hospital by U.S. News & World Report, Rush University Medical Center is one of Chicago's finest academic medical centers and is comprised of Rush University Medical Center, Rush University, Rush Oak Park Hospital and Rush Health. Additional information regarding RUMC is available online at <https://www.rush.edu/>.

Forward-Looking Information

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. In particular, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.



#####